Moleculin Biotech, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Moleculin Biotech, Inc. (MBRX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $436.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-13
- Moleculin Biotech, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $436.00K, a 4.56% increase year-over-year.
- Moleculin Biotech, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $380.00K, a 21.65% decline year-over-year.
- Moleculin Biotech, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $303.00K, a 14.16% decline year-over-year.
- Moleculin Biotech, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $417.00K, a 7.95% decline year-over-year.
- Moleculin Biotech, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $1.66M, a 1.48% decline from fiscal 2024.
- Moleculin Biotech, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $1.69M, a 14.87% decline from fiscal 2023.
- Moleculin Biotech, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $1.98M, a 12.79% decline from fiscal 2022.
- Moleculin Biotech, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $2.27M, a 3.93% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $436.00K 10-Q · filed 2026-08-13 | $816.00K derived: sum of 2 quarters · filed 2026-08-13 | |||
| 2026-03-31 | $380.00K 10-Q · filed 2026-08-13 | ||||
| 2025-12-31 | $1.66M 10-K · filed 2026-03-18 | ||||
| 2025-09-30 | $303.00K 10-Q · filed 2025-11-13 | $720.00K derived: sum of 2 quarters · filed 2026-08-13 | $1.21M derived: sum of 3 quarters · filed 2026-08-13 | ||
| 2025-06-30 | $417.00K 10-Q · filed 2026-08-13 | $902.00K derived: sum of 2 quarters · filed 2026-08-13 | |||
| 2025-03-31 | $485.00K 10-Q · filed 2026-08-13 | ||||
| 2024-12-31 | $1.69M 10-K · filed 2026-03-18 | ||||
| 2024-09-30 | $353.00K 10-Q · filed 2025-11-13 | $806.00K derived: sum of 2 quarters · filed 2025-11-13 | $1.26M derived: sum of 3 quarters · filed 2025-11-13 | ||
| 2024-06-30 | $453.00K 10-Q · filed 2025-11-13 | $909.00K derived: sum of 2 quarters · filed 2025-11-13 | |||
| 2024-03-31 | $456.00K 10-Q · filed 2025-11-13 | ||||
| 2023-12-31 | $1.98M 10-K · filed 2025-03-21 | ||||
| 2023-09-30 | $493.00K 10-Q · filed 2024-11-08 | $1.01M derived: sum of 2 quarters · filed 2024-11-08 | $1.50M derived: sum of 3 quarters · filed 2024-11-08 | ||
| 2023-06-30 | $513.00K 10-Q · filed 2024-11-08 | $1.01M derived: sum of 2 quarters · filed 2024-11-08 | |||
| 2023-03-31 | $499.00K 10-Q · filed 2024-11-08 | ||||
| 2022-12-31 | $2.27M 10-K · filed 2024-03-22 | ||||
| 2022-09-30 | $699.00K 10-Q · filed 2023-11-13 | $1.21M derived: sum of 2 quarters · filed 2023-11-13 | $1.74M derived: sum of 3 quarters · filed 2023-11-13 | ||
| 2022-06-30 | $514.00K 10-Q · filed 2023-11-13 | $1.04M derived: sum of 2 quarters · filed 2023-11-13 | |||
| 2022-03-31 | $527.00K 10-Q · filed 2023-11-13 | ||||
| 2021-12-31 | $2.37M 10-K · filed 2023-03-22 | ||||
| 2021-09-30 | $977.00K 10-Q · filed 2022-11-10 | $1.41M derived: sum of 2 quarters · filed 2022-11-10 | $1.81M derived: sum of 3 quarters · filed 2022-11-10 | ||
| 2021-06-30 | $433.00K 10-Q · filed 2022-11-10 | $838.00K derived: sum of 2 quarters · filed 2022-11-10 | |||
| 2021-03-31 | $405.00K 10-Q · filed 2022-11-10 | ||||
| 2020-12-31 | $1.68M 10-K · filed 2022-03-24 | ||||
| 2020-09-30 | $460.00K 10-Q · filed 2021-11-10 | $868.00K derived: sum of 2 quarters · filed 2021-11-10 | $1.26M derived: sum of 3 quarters · filed 2021-11-10 | ||
| 2020-06-30 | $408.00K 10-Q · filed 2021-11-10 | $805.00K derived: sum of 2 quarters · filed 2021-11-10 | |||
| 2020-03-31 | $397.00K 10-Q · filed 2021-11-10 | ||||
| 2019-12-31 | $1.54M 10-K · filed 2021-03-24 | ||||
| 2019-09-30 | $489.00K 10-Q · filed 2020-11-12 | $807.00K derived: sum of 2 quarters · filed 2020-11-12 | $1.16M derived: sum of 3 quarters · filed 2020-11-12 | $1.47M derived: sum of 4 quarters · filed 2020-11-12 | |
| 2019-06-30 | $318.00K 10-Q · filed 2020-11-12 | $666.00K derived: sum of 2 quarters · filed 2020-11-12 | $981.00K derived: sum of 3 quarters · filed 2020-11-12 | $1.23M derived: sum of 4 quarters · filed 2020-11-12 | |
| 2019-03-31 | $348.00K 10-Q · filed 2020-11-12 | $663.00K derived: sum of 2 quarters · filed 2020-11-12 | $907.00K derived: sum of 3 quarters · filed 2020-11-12 | $1.25M derived: sum of 4 quarters · filed 2020-11-12 | |
| 2018-12-31 | $315.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-19 | $559.00K derived: sum of 2 quarters · filed 2020-03-19 | $898.00K derived: sum of 3 quarters · filed 2020-03-19 | $1.14M 10-K · filed 2020-03-19 | |
| 2018-09-30 | $244.00K 10-Q · filed 2019-11-12 | $583.00K derived: sum of 2 quarters · filed 2019-11-12 | $825.00K 10-Q · filed 2018-11-13 | $1.04M derived: sum of 4 quarters · filed 2019-11-12 | |
| 2018-06-30 | $339.00K 10-Q · filed 2019-11-12 | $581.00K 10-Q · filed 2018-08-10 | $801.00K derived: sum of 3 quarters · filed 2019-11-12 | $1.07M derived: sum of 4 quarters · filed 2019-11-12 | |
| 2018-03-31 | $242.00K 10-Q · filed 2019-11-12 | $462.00K derived: sum of 2 quarters · filed 2019-11-12 | $729.00K derived: sum of 3 quarters · filed 2019-11-12 | $839.00K derived: sum of 4 quarters · filed 2019-11-12 | |
| 2017-12-31 | $220.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-21 | $487.00K derived: sum of 2 quarters · filed 2019-02-21 | $597.00K derived: sum of 3 quarters · filed 2019-02-21 | $707.00K 10-K · filed 2019-02-21 | |
| 2017-09-30 | $267.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | $377.00K derived: sum of 2 quarters · filed 2017-11-13 | $487.00K 10-Q · filed 2017-11-13 | ||
| 2017-06-30 | $110.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11 | $220.00K 10-Q · filed 2017-08-11 | |||
| 2017-03-31 | $110.00K 10-Q · filed 2017-05-12 | ||||
| 2016-12-31 | $166.00K 10-K · filed 2018-03-28 | $166.29K 10-K · filed 2017-04-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |